For the design of artificial antibody-like binding proteins the Affilines Scil Proteins is developing the proprietary Affiline Platform Technology.
In contrast to conventional antibodies the Affilines from Scil Proteins are small, extremely stable and easy to produce in
E. coli. As an alternative to conventional antibodies Affilines open a wide field of potential applications. The fully human composition makes the Affilines an ideal tool for therapeutical application. Furthermore, Affilines enable human, veterinary, food and environmental diagnostics and analytics as well as chromatographic procedures.
A synthetic library constructed by randomisation of surface exposed amino acid residues of a suitable protein scaffold contains the potential binding proteins. Affilines possessing specific binding properties to any desired predefined target are selected from this synthetic library in vitro without the need to immunise animals. This technology enables the generation of specific Affilines for happens, peptides or proteins irrespective of its immunogenic potential or toxicity.
The ease of production of the small and extremely stable Affilines and the convenient selection process makes the Affiline Platform Technology a powerful tool for the generation of tailor-made binding molecules with high specificity. u
ENQUIRY No 79
Scil Proteins GmbH is based in Halle, Germany. www.scilproteins.com
